VNL1.F CHINA HEALTH GRP HD-10
- Market cap
- EUR 1.11M
- P/E
- -
- P/B
- 0.06x
- ROE
- -27.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is VNL1.F undervalued?
Graham numberThe Graham number of CHINA HEALTH GRP HD-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CHINA HEALTH GRP HD-10 fundamental analysis
No fundamental analysis for CHINA HEALTH GRP HD-10 yet.
CHINA HEALTH GRP HD-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CHINA HEALTH GRP HD-10
China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China. It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Heal…
Full company profileCHINA HEALTH GRP HD-10 financial statements
CHINA HEALTH GRP HD-10 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 83.6M | 13.1M | 21.4M | 26.5M | 28.6M |
| Gross Profit | 63.9M | 5.74M | 8.21M | 10.1M | 16.4M |
| Operating Income | 42.1M | -16.1M | -58.3M | -14.8M | -15.2M |
| EBITDA | - | -15.7M | -58.1M | -14.2M | -14.4M |
| Net Income | 36.3M | -15.8M | -58.0M | -14.5M | -15.0M |
| EPS | 0.04 | -0.02 | -0.06 | -0.01 | -0.02 |
| Balance Sheet | |||||
| Total Assets | 194M | 179M | 119M | 101M | 87.1M |
| Total Liabilities | 38.8M | 36.7M | 35.2M | 31.2M | 32.3M |
| Shareholders' Equity | 156M | 142M | 84.8M | 70.4M | 55.4M |
| Cash & Short-term Investments | 11.4M | 4.06M | 4.14M | 14.2M | 21.8M |
| Cash Flow | |||||
| Operating Cash Flow | -10.3M | -5.16M | 1.12M | 10.3M | 7.59M |
| Capital Expenditure | 0.00 | 0.00 | 6.00M | 1.76M | 10.0K |
| Free Cash Flow | -10.3M | -5.16M | -4.88M | 8.52M | 7.58M |
| Ratios | |||||
| ROE | 23.3% | -11.1% | -68.4% | -20.6% | -27.0% |
| ROA | 18.7% | -8.9% | -48.6% | -14.4% | -17.2% |
| Net Profit Margin | 43.5% | -120.9% | -270.8% | -54.9% | -52.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CHINA HEALTH GRP HD-10 dividends
CHINA HEALTH GRP HD-10 has not paid dividends in the last 5 fiscal years.
Who owns CHINA HEALTH GRP HD-10
- Insiders 70.98%
- Institutions 0.00%
- Public & others 29.02%
- Shares outstanding 995M
- Free float 289M
CHINA HEALTH GRP HD-10 company profile
- Company name
- CHINA HEALTH GRP HD-10
- Ticker
- VNL1.F
- ISIN
- KYG2117N1088
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- Building 17, Beijing, China
- Phone
- 86 21 6115 8121
- Website
- chgi.net
About CHINA HEALTH GRP HD-10
China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China. It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in February 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, China.
CHINA HEALTH GRP HD-10 management
7- Mr. Xia Guo MBA, MSc, Ph.D.Executive Chairman · born 1965
- Mr. Guo RaymondExecutive Director & Chief Artificial Intelligence Officer · born 2001
- Mr. Liang LiFinancial Director
- Dr. Tuo JinJoint Chief Technology Officer and Member of Scientific Advisory Board · born 1953
- Dr. Xuemei SongHead of HR Mgmt Dept · born 1968
- Mr. Tsz Ngo YuCompany Secretary · born 1986
- Dr. Yiu Kwong Sun B.S., M.B., M.D.Adviser for Medical Affairs and Member of Corporate Advisory Board · born 1943